Barclays Cuts bluebird bio (NASDAQ:BLUE) Price Target to $8.00

bluebird bio (NASDAQ:BLUE – Get Free Report) had its target price reduced by Barclays from $40.00 to $8.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s price objective would suggest a potential upside of 52.38% from the stock’s previous close. Several other equities […]